CDMO RoslinCT reports that it will manufacture the world’s first CRISPR-based therapy, exa-cel, across the world as part of the global manufacturing network for Vertex Pharmaceuticals. Exa-cel (brand name Casgevy^TM) is a new treatment for sickle cell disease and transfusion-dependent beta thalassemia, authorized by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) on November 15. Source: Genetic Engineering News 29/11/2023